8-KItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements

Moderna ($MRNA) filed Form 8-K (Item 9.01) on Jan 5, 2026 — Exhibit 99.1 is a shareholder letter dated Jan…

Filed with the SEC on January 5, 2026 · Summarized by InvestorsBot

Moderna ($MRNA) filed Form 8-K (Item 9.01) on Jan 5, 2026 — Exhibit 99.1 is a shareholder letter dated Jan 5, 2026. Filing signed by Chief Legal Officer Shannon Thyme Klinger. 📝 $MRNA #SECfiling #InvestorUpdate

Item 9.01 discloses exhibits only: Exhibit 99.1 (shareholder letter) and Exhibit 104 (Inline XBRL cover page). No new financial statements or schedules reported. 🔎 $MRNA #XBRL #Moderna

Investors should review Exhibit 99.1 on EDGAR for any management commentary or material corporate updates referenced in the Jan 5, 2026 filing. 🔍 $MRNA #SECfiling #InvestorUpdate

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from Moderna, Inc.

BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering…

8-K · March 5, 2026

Moderna filed a Form 8‑K on Feb 13, 2026 furnishing a press release (Exhibit 99.1).

8-K · February 13, 2026

Moderna ($MRNA) announced Q4 2025 financial results on Feb 13, 2026 for the quarter ended Dec 31, 2025 —…

8-K · February 13, 2026

Moderna ($MRNA) filed an 8‑K (Item 9.01) on Feb 10, 2026 — Exhibit 99.1: press release dated Feb 10, 2026;…

8-K · February 11, 2026

FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will…

8-K · February 11, 2026

Moderna ($MRNA) said on Feb 10, 2026 it received a Refusal-to-File letter from the FDA for its…

8-K · February 11, 2026